Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Ajovy

PharmaCompass

01

Brand Name : Ajovy

Fremanezumab

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Ajovy

arrow
Fi Europe 2024
Not Confirmed

Fremanezumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 93

2018 Revenue in Millions : 3

Growth (%) : 3,000

blank

02

Brand Name : Ajovy

Fremanezumab

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Ajovy

arrow
Fi Europe 2024
Not Confirmed

Fremanezumab

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 165

2019 Revenue in Millions : 96

Growth (%) : 72

blank

03

Brand Name : Ajovy

Fremanezumab

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Ajovy

arrow
Fi Europe 2024
Not Confirmed

Fremanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 313

2020 Revenue in Millions : 165

Growth (%) : 90

blank

04

Brand Name : Ajovy

Fremanezumab

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Ajovy

arrow
Fi Europe 2024
Not Confirmed

Fremanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 377

2021 Revenue in Millions : 313

Growth (%) : 20

blank

05

Brand Name : Ajovy

Fremanezumab

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Ajovy

arrow
Fi Europe 2024
Not Confirmed

Fremanezumab

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 434

2022 Revenue in Millions : 377

Growth (%) : 15

blank